Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Others

Aptevo Therapeutics (APVO) Goodwill (2016)

Aptevo Therapeutics (APVO) has disclosed Goodwill for 2 consecutive years, with $29.2 million as the latest value for Q2 2016.

Quarterly Goodwill changed N/A to $29.2 million in Q2 2016 from the year-ago period, while the trailing twelve-month figure was $29.2 million through Jun 2016, changed N/A year-over-year, with the annual reading at $29.2 million for FY2015, N/A changed from the prior year.
Goodwill hit $29.2 million in Q2 2016 for Aptevo Therapeutics, roughly flat from $29.2 million in the prior quarter.
In the past five years, Goodwill ranged from a high of $29.2 million in Q4 2015 to a low of $29.2 million in Q4 2015.